Pharsight

Par Sterile Products patents expiration

1. Adrenalin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295657 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(10 years from now)

US9119876 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(10 years from now)

US10130592 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(10 years from now)

US10653646 PAR STERILE PRODUCTS Epinephrine compositions and containers
Mar, 2039

(14 years from now)

US11207280 PAR STERILE PRODUCTS Epinephrine compositions and containers
Mar, 2039

(14 years from now)

US11083698 PAR STERILE PRODUCTS Epinephrine compositions and containers
Mar, 2039

(14 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis; To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of ADRENALIN before it's drug patent expiration?
More Information on Dosage

ADRENALIN family patents

Family Patents

2. Vasostrict patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375478 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9925233 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US10010575 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9974827 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9968649 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9962422 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9925234 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9981006 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9687526 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9919026 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9750785 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9744209 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9937223 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

US9744239 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(10 years from now)

Drugs and Companies using VASOPRESSIN ingredient

Market Authorisation Date: 17 April, 2014

Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of VASOSTRICT before it's drug patent expiration?
More Information on Dosage

VASOSTRICT family patents

Family Patents